"NEW YORK (TheStreet) -- Boston Scientific (NYSE:BSX) has been downgraded by TheStreet Ratings from hold to sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and generally disappointing historical performance in the stock itself."
The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 2431.5% when compared to the same quarter one year ago, falling from $146.00 million to -$3,404.00 million.
Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, BOSTON SCIENTIFIC CORP's return on equity significantly trails that of both the industry average and the S&P 500.
Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 27.98%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 2490.00% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
That press release is computer generated and also took into account the 3.4bil "NON-CASH" charge. Take out that one time, non-recurring, non-cash charge, and you don't have a loss for the quarter.
This is an easy double from here within 2 years. Where else can you get a return like that? BSX is going to turn the revenue picture around. Meanwhile they are taking shares off the open market thru the buyback. I hope you fine a better entry point than here?
JNJ could come in at $10/share and get themselves back into the stent market. Now that JNJ has not been selling stents themselves, there is no anti-trust hurdles. I wouldn't rule out a joint purchase by ABT and JNJ. Either way, BSX will be at $10 either thru a purchase, or on it's own.